Pharmacology of warfarin and clinical implications

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 1, 1999, Pages 13-16

  Keller, Christina ^a,b   Matzdorff, Axel C ^a   Kemkes Matthes, Bettina ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Coumarin; Oral anticoagulants; Pharmacological properties; Vitamin K; Warfarin

Indexed keywords

ACENOCOUMAROL; ALBUMIN; ANTICOAGULANT AGENT; DICOUMAROL; PHENPROCOUMON; PROTEIN C; PROTHROMBIN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CLINICAL PRACTICE; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG UTILIZATION; HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEADY STATE; VITAMIN METABOLISM;

EID: 0032908495     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996418     Document Type: Article

References (9)

1. 1. Link KP. The discovery of dicumarol and its sequels. Circulation 1959;19:97-108
2. 2. Koller T, Merz WR, Eds. Thrombosis and Embolism. Basel, Benno Schwabe Co; 1955:1234-1236
3. 3. O'Reilly RA. Vergleich der klinischen Pharmakologie von Warfarin mit Phenprocoumon. Hämostaseologie 1997;17:145-148
4. 4. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324:1865-1875
5. 5. Keron C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-1511
6. 6. Viganò S, Mannucci PM, Solinas S, et al. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 1984;57:213-220
7. 7. Kemkes-Matthes B, Heinrich D, Dapper F, Lasch HG. Kumarinnekrose bei Protein C-Mangel. Med Welt 1988;39:72-75
8. 8. Thijssen HHW, Hamulyák K, Willigers H. 4-Hydroxycoumarin oral anticoagulants: Pharmacokinetics-response relationship. Thromb Haemostas 1988;60:35-38
9. 9. Matzdorff, A, Kemkes-Matthes, B. Therapie mit oralen Antikoagulanzien.